QUEST DIAGNOSTICS INC Insider Trading Activity
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 108 shares of common stock on April 20, 2026, at $194.698 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 108 shares of common stock on April 20, 2026, at $194.698 per share. After this award, he holds 33,376 shares directly.
Footnotes state the transaction represents an award of restricted share units and reflects shares acquired through a dividend reinvestment plan administered by his broker, which he chose to report early rather than on a later Form 5.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 108 | $194.698 | $21K |
Footnotes (2)
- F1. Represents an award of restricted share units.
- F2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Key Terms
dividend reinvestment plan financial
deferred reporting on Form 5 regulatory
grant, award, or other acquisition regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Quest Diagnostics (DGX) report for Sam Samad?
Why does the Quest Diagnostics (DGX) Form 4 mention deferred reporting on Form 5?
AI-generated analysis. How Rhea-AI works. Not financial advice.